Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39

Tian,Wenxia; Li,Bing; Zhang,Xiwen; Dang,Weiqi; Wang,Xiaofei; Tang,Hao; Wang,Lin; Cao,Hong; Chen,Tingmei

doi:10.3892/or.2012.1911

Suppression of tumor invasion and migration in breast cancer cells following delivery of siRNA against Stat3 with the antimicrobial peptide PR39

Authors:
- Wenxia Tian
- Bing Li
- Xiwen Zhang
- Weiqi Dang
- Xiaofei Wang
- Hao Tang
- Lin Wang
- Hong Cao
- Tingmei Chen
View Affiliations

Affiliations: Department of Laboratory Medicine, Key Laboratory of Diagnostic Medicine, Ministry of Education, Chongqing Medical University, Chongqing 400016, P.R. China, Dean's Office of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: July 13, 2012 https://doi.org/10.3892/or.2012.1911
Pages: 1362-1368

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

PR39, a porcine cathelicidin rich in the amino acids proline and arginine can interact with the negatively charged component of the cell surface, and rapidly penetrate cell membranes. Therefore, we hypothesized that PR39, as a membrane penetrating peptide (MPP), could be exploited as a novel carrier to deliver siRNA into the cell cytoplasm in order to knockdown target gene expression. Firstly, a complex formation of PR39 with siRNA and its cellular colocalization were investigated in our studies. Further, we optimized the ratio of the PR39/siRNA complex, cell/complex incubation period and the concentration of siRNA. The results suggest that PR39 could form a complex with siRNA, and mediate translocation of the siRNA into 4T1 cells. The optimal ratio of siRNA with PR39 was 1:90 which was found to have a maximum Stat3 gene silencing effect after 48 h treatment. Moreover, 4T1 cell proliferation, cell cycle, invasion and migration were investigated. The results suggested that Stat3 knockdown could not result in 4T1 cell proliferation inhibition and cell cycle arrest, while invasion and migration of 4T1 cells were strongly inhibited. Notably, the data also showed that in addition to inhibition of carcinogenesis, single PR39 may play a role in cell invasion and migration. PR39 and Stat3 siRNA displayed synergistic biological effects in inhibiting cell invasion and migration of 4T1 cells, which was more prominent compared with the popular Lipofectamine delivery system.

View Figures

View References

1	Yang SY: Sniper the hyperplasia of mammary glands and escort for the women health. Med People. 34–35. 2007.
2	Jun JY, Griffith JW, Bruggeman R, et al: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat. 107:33–40. 2008.PubMed/NCBI
3	Garcia R, Yu CL, Hudnall A, et al: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 8:1267–1276. 1997.PubMed/NCBI
4	Yu H and Jove R: The STATs of cancer – new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004.
5	Frank DA: STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett. 251:199–210. 2007. View Article : Google Scholar : PubMed/NCBI
6	Darnell JE Jr: Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2:740–749. 2002. View Article : Google Scholar : PubMed/NCBI
7	Chiu WT, Lee HT, Huang FJ, et al: Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res. 71:4932–4943. 2011. View Article : Google Scholar : PubMed/NCBI
8	Blaskovich MA, Sun J, Cantor A, et al: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 63:1270–1279. 2003.
9	Leong PL, Andrews GA, Johnson DE, et al: Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA. 100:4138–4143. 2003. View Article : Google Scholar : PubMed/NCBI
10	Meydan N, Grunberger T, Dadi H, et al: Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 379:645–648. 1996. View Article : Google Scholar : PubMed/NCBI
11	Mora LB, Buettner R, Seigne J, et al: Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
12	Nakajima K, Yamanaka Y, Nakae K, et al: A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J. 15:3651–3658. 1996.PubMed/NCBI
13	Ni Z, Lou W, Leman ES, et al: Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 60:1225–1228. 2000.PubMed/NCBI
14	de Fougerolles A, Vornlocher HP, Maraganore J and Liberman J: Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 6:443–453. 2007.PubMed/NCBI
15	Akhtar S and Benter I: Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. Adv Drug Deliv Rev. 59:164–182. 2007. View Article : Google Scholar : PubMed/NCBI
16	Bumcrot D, Manoharan M, Koteliansky V and Sah DW: RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2:711–719. 2006. View Article : Google Scholar : PubMed/NCBI
17	Nakamura Y, Kogure K, Futaki S and Harashima H: Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release. 119:360–367. 2007. View Article : Google Scholar : PubMed/NCBI
18	Agerberth B, Lee JY, Bergman T, et al: Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. Eur J Biochem. 202:849–854. 1991. View Article : Google Scholar : PubMed/NCBI
19	Boman HG, Agerberth B and Boman A: Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect Immun. 61:2978–2984. 1993.PubMed/NCBI
20	Storici P and Zanetti M: A cDNA derived from pig bone marrow cells predicts a sequence identical to the intestinal antibacterial peptide PR-39. Biochem Biophys Res Commun. 196:1058–1065. 1993. View Article : Google Scholar : PubMed/NCBI
21	Shi J, Ross CR, Leto TL and Blecha F: PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47phox. Proc Nat Acad Sci USA. 93:6014–6018. 1996. View Article : Google Scholar : PubMed/NCBI
22	Chan YR and Gallo RL: PR-39, a syndecan-inducing antimicrobial peptide, binds and affects p130(Cas). J Biol Chem. 273:28978–28985. 1998. View Article : Google Scholar : PubMed/NCBI
23	Gao Y, Lecker S, Post MJ, et al: Inhibition of ubiquitin-proteasome pathway–mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest. 106:439–448. 2000.
24	Alshamsan A, Hamdy S, Samuel J, et al: The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials. 31:1420–1428. 2010. View Article : Google Scholar : PubMed/NCBI
25	Ye Y, Yin DT, Chen L, et al: Identification of Piwil2-like (PL2L) proteins that promote tumorigenesis. PLoS One. 5:e134062010. View Article : Google Scholar : PubMed/NCBI
26	Ohtake T, Fujimoto Y, Ikuta K, et al: Proline-rich antimicrobial peptide, PR39 gene transduction altered invasive activity and actin structure in human hepatocellular carcinoma cells. Br J Cancer. 81:393–403. 1999. View Article : Google Scholar
27	Ohki EC, Tilkins ML, Ciccarone VC and Price PJ: Improving the transfection efficiency of post-mitotic neurons. J Neurosci Methods. 112:95–99. 2001. View Article : Google Scholar : PubMed/NCBI
28	Wang YH, Chen CP, Chan MH, et al: Arginine-rich intracellular delivery peptides noncovalently transport protein into living cells. Biochem Biophys Res Commun. 346:758–767. 2006. View Article : Google Scholar : PubMed/NCBI
29	Wang YH, Hou YW and Lee HJ: An intracellular delivery method for siRNA by an arginine-rich peptide. J Biochem Biophys Methods. 70:579–586. 2007. View Article : Google Scholar : PubMed/NCBI
30	Kim SW, Kim NY, Choi YB, et al: RNA interference in vitro and in vivo using an arginine peptide/siRNA complex system. J Control Release. 143:335–343. 2010.PubMed/NCBI
31	Zhang X, Oglecka K, Sandgren S, et al: Dual functions of the human antimicrobial peptide LL-37-target membrane perturbation and host cell cargo delivery. Biochim Biophys Acta. 1798:2201–2208. 2010. View Article : Google Scholar : PubMed/NCBI
32	Hoskin DW and Ramamoorthy A: Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta. 1778:357–375. 2008. View Article : Google Scholar : PubMed/NCBI
33	Veldhoen S, Laufer SD, Trampe A and Restle T: Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res. 34:6561–6573. 2006. View Article : Google Scholar : PubMed/NCBI